With this launch, the company has entered the prescription dermatology segment in Brazil, Lupin said in a statement to the exchanges on Thursday. Fillerina is a high-end anti-aging technology, while Recrexina is a hair-growth formulation, the company added.
As a part of the launch, the pharma company has also launched a 360-degree communications campaign in Brazil focusing on healthcare professionals, pharmacy chains, and regional and national medical associations.
Lupin share is currently at Rs903.50, up by Rs14.3 or 1.61% from its previous closing of Rs889.20 on the BSE.
The scrip opened at Rs900, and has touched a high and low of Rs916.85 and Rs892.80, respectively. So far, 36,91,380 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs40,205.47cr.